The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes
Subbaramaiah, K., Marmo, T. P., Dixon, D. A., & Dannenberg, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301481200 · Cited by 195
RetractedVeuger, S. J., Hunter, J. E., & Durkacz, B. W. (2008) · Oncogene · doi:10.1038/onc.2008.439 · Cited by 135
RetractedRegulation and Function of NF-κB Transcription Factors in the Immune System
Vallabhapurapu, S., & Karin, M. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132641 · Cited by 2,588
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Transcriptional Regulation by Extracellular signals: Mechanisms and Specificity
Hill, C. S., & Treisman, R. (1995) · Cell · doi:10.1016/0092-8674(95)90403-4 · Cited by 1,012
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Induction of NF-κB by the Akt/PKB kinase
Kane, L. P., Shapiro, V. S., Stokoe, D., & Weiss, A. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80265-6 · Cited by 846
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0746 · Cited by 765
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
Nakanishi, C., & Toi, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1588 · Cited by 724
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Yamamoto, K., Arakawa, T., Ueda, N., & Yamamoto, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31315 · Cited by 647
Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B. R., & Lipp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.1.211 · Cited by 635
Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., & Aggarwal, B. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4257 · Cited by 578
Sizemore, N., Leung, S., & Stark, G. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4798 · Cited by 557
Tamatani, M., Che, Y. H., Matsuzaki, H., Ogawa, S., Okado, H., Miyake, S.-I., Mizuno, T., & Tohyama, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8531 · Cited by 549
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer
Catz, S. D., & Johnson, J. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204926 · Cited by 538
Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic Stimuli
Wu, Z.-H., Shi, Y., Tibbetts, R. S., & Miyamoto, S. (2006) · Science · doi:10.1126/science.1121513 · Cited by 515
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
Arlt, A., Gehrz, A., Müerköster, S., Vorndamm, J., Kruse, M.-L., Fölsch, U. R., & Schäfer, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206390 · Cited by 474
Targeting cyclooxygenase-2 in human neoplasia
Dannenberg, A. J., & Subbaramaiah, K. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00310-6 · Cited by 446
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms
Li, N., & Karin, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13012 · Cited by 427
Nuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
Self-citationNuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
Ionizing radiation induces expression and binding activity of the nuclear factor kappa B.
Brach, M. A., Hass, R., Sherman, M. L., Gunji, H., Weichselbaum, R., & Kufe, D. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115354 · Cited by 408
An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson, S. A., Myers, T. G., Scudiero, D. A., Kitada, S., Reed, J. C., & Fornace, A. J. (2000) · PubMed · Cited by 408
Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., & Sarkar, F. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4604 · Cited by 376
Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., & Huang, H.-J. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5724 · Cited by 363
Akimoto, T., Hunter, N. R., Buchmiller, L., Mason, K. A., Ang, K. K., & Milas, L. (1999) · PubMed · Cited by 357
Bussink, J., van der Kogel, A. J., & Kaanders, J. H. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70073-1 · Cited by 326
PIDD Mediates NF-κB Activation in Response to DNA Damage
Janssens, S., Tinel, A., Lippens, S., & Tschopp, J. (2005) · Cell · doi:10.1016/j.cell.2005.09.036 · Cited by 319
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
p53 stabilization is decreased upon NFκB activation
Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., & Verma, I. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 313
Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2
Subbaramaiah, K., Hart, J. C., Norton, L., & Dannenberg, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.14838 · Cited by 300
Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
The epidermal growth factor receptor mediates radioresistance
Liang, K., Ang, K. K., Milas, L., Hunter, N., & Fan, Z. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00511-x · Cited by 292
Rödel, F., Hoffmann, J., Distel, L., Herrmann, M., Noisternig, T., Papadopoulos, T., Sauer, R., & Rödel, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3028 · Cited by 292
Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols
Garg, A. K., Buchholz, T. A., & Aggarwal, B. B. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1630 · Cited by 278
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.
Kishi, K., Petersen, S. H., Petersen, C., Hunter, N. R., Mason, K. A., Masferrer, J. L., Tofilon, P. J., & Milas, L. (2000) · PubMed · Cited by 275
NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy
Shen, H.-M., & Tergaonkar, V. (2009) · Apoptosis · doi:10.1007/s10495-009-0315-0 · Cited by 275
Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B.
Rosette, C., & Karin, M. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.6.1111 · Cited by 272
Sarkaria, J. N., Carlson, B. L., Schroeder, M. A., Grogan, P., Brown, P. D., Giannini, C., Ballman, K. V., Kitange, G. J., Guha, A., Pandita, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2510 · Cited by 270
Activation of NF-κB by Antineoplastic Agents
Das, K. C., & White, C. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14914 · Cited by 269
Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.
Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., & Beger, H. G. (1997) · PubMed · Cited by 261
Criswell, T., Leskov, K., Miyamoto, S., Luo, G., & Boothman, D. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206680 · Cited by 248
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas.
de Palazzo, I. G., Adams, G. P., Sundareshan, P., Wong, A. J., Testa, J. R., Bigner, D. D., & Weiner, L. M. (1993) · PubMed · Cited by 243
Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., & Murata, Y. (2000) · PubMed · Cited by 243
Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M., Wang, Z., Chiao, P. J., Philip, P. A., Abbruzzese, J., & Sarkar, F. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1330 · Cited by 231
Kao, G. D., Jiang, Z., Fernandes, A. M., Gupta, A. K., & Maity, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703042200 · Cited by 228
Arlt, A., Vorndamm, J., Breitenbroich, M., Fölsch, U. R., Kalthoff, H., Schmidt, W. E., & Schäfer, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204168 · Cited by 227
Wang, W., McLeod, H. L., & Cassidy, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.10972 · Cited by 226
PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress
Mabb, A. M., Wuerzberger-Davis, S. M., & Miyamoto, S. (2006) · Nature Cell Biology · doi:10.1038/ncb1458 · Cited by 226
Sequential DNA damage-independent and -dependent activation of NF-kappa B by UV
Bender, K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5170 · Cited by 223
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Kunnumakkara, A. B., Diagaradjane, P., Guha, S., Deorukhkar, A., Shentu, S., Aggarwal, B. B., & Krishnan, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4722 · Cited by 217
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313709200 · Cited by 211
Als, A. B., Dyrskjøt, L., von der Maase, H., Koed, K., Mansilla, F., Toldbod, H. E., Jensen, J. L., Ulhøi, B. P., Sengeløv, L., Jensen, K. M. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0109 · Cited by 206
Survivin as a Radioresistance Factor in Pancreatic Cancer
Asanuma, K., Moriai, R., Yajima, T., Yagihashi, A., Yamada, M., Kobayashi, D., & Watanabe, N. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00906.x · Cited by 205
Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol
Fulda, S., & Debatin, K.-M. (2004) · Oncogene · doi:10.1038/sj.onc.1207630 · Cited by 204
AKT/PKB signaling mechanisms in cancer and chemoresistance
Kim, D. (2005) · Frontiers in Bioscience · doi:10.2741/1592 · Cited by 204
Yu, H., Ai, Y., Yu, L., Zhou, X., Liu, J., Li, J., Xu, X., Liu, S., Chen, J., Liu, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23049 · Cited by 203
Kunnumakkara, A. B., Diagaradjane, P., Anand, P., Kuzhuvelil, H. B., Deorukhkar, A., Gelovani, J., Guha, S., Krishnan, S., & Aggarwal, B. B. (2009) · International Journal of Cancer · doi:10.1002/ijc.24593 · Cited by 199
Activation of PI3K/Akt signaling and hormone resistance in breast cancer
Tokunaga, E., Kimura, Y., Mashino, K., Oki, E., Kataoka, A., Ohno, S., Morita, M., Kakeji, Y., Baba, H., & Maehara, Y. (2006) · Breast Cancer · doi:10.2325/jbcs.13.137 · Cited by 199
Roles of NF-κB in health and disease: mechanisms and therapeutic potential
Wong, E. T., & Tergaonkar, V. (2009) · Clinical Science · doi:10.1042/cs20080502 · Cited by 196
Trifan, O. C., Durham, W. F., Salazar, V. S., Horton, J., Levine, B. D., Zweifel, B. S., Davis, T. W., & Masferrer, J. L. (2002) · PubMed · Cited by 195
Akt Is a Downstream Target of NF-κB
Meng, F., Liu, L., Chin, P. C., & D'Mello, S. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112464200 · Cited by 193
(2001) · PubMed · Cited by 193
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells
Li, H.-F., Kim, J.-S., & Waldman, T. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-43 · Cited by 190
Liu, L.-Z., Zhou, X.-D., Qian, G., Shi, X., Fang, J., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4261 · Cited by 189
ATM Is Required for IκB Kinase (IKK) Activation in Response to DNA Double Strand Breaks
Li, N., Banin, S., Ouyang, H., Li, G. C., Courtois, G., Shiloh, Y., Karin, M., & Rotman, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009809200 · Cited by 188
Gupta, A. K., Cerniglia, G. J., Mick, R., Ahmed, M. S., Bakanauskas, V. J., Muschel, R. J., & McKenna, W. G. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00214-1 · Cited by 184
Sandur, S. K., Deorukhkar, A., Pandey, M. K., Pabón, A. M., Shentu, S., Guha, S., Aggarwal, B. B., & Krishnan, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.034 · Cited by 183
Biliran, H., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., & Liao, J. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2419 · Cited by 181
Kim, I.-A., Bae, S.-S., Fernandes, A., Wu, J., Muschel, R. J., McKenna, W. G., Birnbaum, M. J., & Bernhard, E. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0513 · Cited by 179
Tokunaga, E., Kimura, Y., Oki, E., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., Baba, H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21358 · Cited by 177
The ATM protein is required for sustained activation of NF-κB following DNA damage
Piret, B., Schoonbroodt, S., & Piette, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202541 · Cited by 176 · cited 1×
“acts as a DNA damage sensor, is required for IKK activation [16,17].”
BackgroundPotential pharmacological control of the NF-κB pathway
Sethi, G., & Tergaonkar, V. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.004 · Cited by 171
Self-citationLi, B., Yuan, M., Kim, I.-A., Chang, C.-M., Bernhard, E. J., & Shu, H.-K. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207602 · Cited by 168
Dong, Q. G., Sclabas, G. M., Fujioka, S., Schmidt, C., Peng, B., Wu, T., Tsao, M.-S., Evans, D. B., Abbruzzese, J. L., McDonnell, T. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205848 · Cited by 166
Tolcher, A. W., Chi, K., Kuhn, J., Gleave, M., Patnaik, A., Takimoto, C., Schwartz, G., Thompson, I., Berg, K., D'Aloisio, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2145 · Cited by 166
Huang, Y., Johnson, K. R., Norris, J. S., & Fan, W. (2000) · PubMed · Cited by 163
NF-κB-Mediated HER2 Overexpression inRadiation-Adaptive Resistance
Cao, N., Li, S., Wang, Z., Ahmed, K. M., Degnan, M. E., Fan, M., Dynlacht, J. R., & Li, J. J. (2009) · Radiation Research · doi:10.1667/rr1472.1 · Cited by 162
Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies
Milas, L., Fan, Z., Andratschke, N. H., & Ang, K. K. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.08.035 · Cited by 162
Cao, C., Mu, Y., Hallahan, D. E., & Lu, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207929 · Cited by 161
Tergaonkar, V., Bottero, V., Ikawa, M., Li, Q., & Verma, I. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8070-8083.2003 · Cited by 161
Learn, C. A., Hartzell, T. L., Wikstrand, C. J., Archer, G. E., Rich, J. N., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0521 · Cited by 160
Chuang, S.-E., Yeh, P.-Y., Lu, Y.-S., Lai, G.-M., Liao, C.-M., Gao, M., & Cheng, A.-L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00931-0 · Cited by 159
Gaffney, D. K., Holden, J. A., Davis, M., Zempolich, K. A., Murphy, K. J., & Dodson, M. W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01583-2 · Cited by 152
Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3
Chen, X., Yeung, T. K., & Wang, Z. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3731 · Cited by 151
Toulany, M., Dittmann, K., Krüger, M., Baumann, M. A., & Rodemann, H. P. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.024 · Cited by 151
Zhang, L., Lau, Y. K. J., Xia, W., Hortobágyi, G. N., & Hung, M. (1999) · PubMed · Cited by 150
Sung, B., Kunnumakkara, A. B., Sethi, G., Anand, P., Guha, S., & Aggarwal, B. B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0905 · Cited by 150
Self-citationCheng, J. Q., Jiang, X., Fraser, M. E., Li, M., Dan, H. C., Sun, M., & Tsang, B. K. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00003-1 · Cited by 149
Kawakami, H., Tomita, M., Matsuda, T., Ohta, T., Tanaka, Y., Fujii, M., Hatano, M., Tokuhisa, T., & Mori, N. (2005) · International Journal of Cancer · doi:10.1002/ijc.20954 · Cited by 148
Kim, D.-S., Park, S. S., Nam, B., Kim, I.-H., & Kim, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1521 · Cited by 143
Kornmann, M., Arber, N., & Korc, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1323 · Cited by 142
A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB
Lee, S.-J., Dimtchev, A., Lavin, M. F., Dritschilo, A., & Jung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202088 · Cited by 136
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 136
Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
Huang, W., & Hung, M. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60051-6 · Cited by 135
L’Espérance, S., Popa, I., Bachvarova, M., Plante, M., Patten, N., Wu, L., Têtu, B., & Bachvarov, D. R. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.5 · Cited by 134
Bottero, V., Busuttil, V., Loubat, A., Magné, N., Fischel, J., Milano, G. A., & Peyron, J. (2001) · PubMed · Cited by 132
Abedini, M. R., Muller, É., Bergeron, R., Gray, D. A., & Tsang, B. K. (2009) · Oncogene · doi:10.1038/onc.2009.300 · Cited by 130
Antitumor and Radiosensitizing Effects of Withaferin a on Mouse Ehrlich Ascites Carcinoma in vivo
Sharada, A. C., Solomon, F. E., Devi, P. U., Udupa, N., & Srinivasan, K. K. (1996) · Acta Oncologica · doi:10.3109/02841869609098486 · Cited by 129
Zemskova, M., Sahakian, E., Bashkirova, S., & Lilly, M. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709479200 · Cited by 129
Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
Koki, A. T., Leahy, K. M., & Masferrer, J. L. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1623 · Cited by 124
Murtaza, I., Adhami, V. M., Hafeez, B. B., Saleem, M., & Mukhtar, H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24628 · Cited by 122
Liang, K., Jin, W., Knuefermann, C., Schmidt, M., Mills, G. B., Ang, K. K., Milas, L., & Fan, Z. (2003) · PubMed · Cited by 122
Shao, R., Karunagaran, D., Zhou, B. P., Li, K., Lo, S.-S., Deng, J., Chiao, P. J., & Hung, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.32739 · Cited by 121
Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells
Piret, B., & Piette, J. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.21.4242 · Cited by 121
Tamburini, J., Elie, C., Bardet, V., Chapuis, N., Park, S., Broët, P., Cornillet-Lefebvre, P., Lioure, B., Ugo, V., Blanchet, O., et al. (2007) · Blood · doi:10.1182/blood-2006-12-061283 · Cited by 120
Fujiwara, K., Iwado, E., Mills, G. B., Sawaya, R. A., Kondo, S., & Kondo, Y. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.753 · Cited by 119
The DNA-Dependent Protein Kinase Participates in the Activation of NFκB Following DNA Damage
Basu, S., Rosenzweig, K. R., Youmell, M., & Price, B. D. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8741 · Cited by 116
Nakagawa, Y., Abe, S., Kurata, M., et al. (2006) · American Journal of Hematology · doi:10.1002/ajh.20656 · Cited by 116
Trask, D. K., Wolf, G. T., Bradford, C. R., Fisher, S. G., Devaney, K. O., Johnson, M., Singleton, T. P., & Wicha, M. S. (2002) · The Laryngoscope · doi:10.1097/00005537-200204000-00009 · Cited by 115
Lee, J.-U., Hosotani, R., Wada, M., Doi, R., Kosiba, T., Fujimoto, K., Miyamoto, Y., Tsuji, S., Nakajima, S., Nishimura, Y., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00134-3 · Cited by 114
Tanno, S., Yanagawa, N., Habiro, A., Koizumi, K., Nakano, Y., Osanai, M., Mizukami, Y., Okumura, T., Testa, J. R., & Kohgo, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1788 · Cited by 113
Kornmann, M., Danenberg, K. D., Arber, N., Beger, H. G., Danenberg, P. V., & Korc, M. (1999) · PubMed · Cited by 113
AKT involvement in cisplatin chemoresistance of human uterine cancer cells
Gagnon, V., Mathieu, I., Sexton, É., Leblanc, K., & Asselin, É. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.023 · Cited by 112
Dolcet, X., Llobet‐Navàs, D., Encinas, M., Pallarés, J., Cabero, A., Schoenenberger-Arnaiz, J. A., Comella, J. X., & Matías‐Guiu, X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601350200 · Cited by 111
Zoberi, I., Bradbury, C. M., Curry, H. A., Bisht, K. S., Goswami, P. C., Roti, J. L. R., & Gius, D. R. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00719-4 · Cited by 110
Bcl-2 expression predicts radiotherapy failure in laryngeal cancer
Nix, P., Cawkwell, L., Patmore, H. S., Greenman, J., & Stafford, N. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602647 · Cited by 110
Inhibition of NF-κB sensitizes non–small cell lung cancer cells to chemotherapy-induced apoptosis
Jones, D. R., Broad, R. M., Madrid, L. V., Baldwin, A. S., & Mayo, M. W. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01635-0 · Cited by 109
Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced Apoptosis
Denlinger, C. E., Rundall, B. K., Keller, M. D., et al. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2004.04.029 · Cited by 109
Zhu, L., Fukuda, S., Cordis, G. A., Das, D. K., & Maulik, N. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03084-8 · Cited by 108
Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells
Wang, T., Wei, J., Qian, X., Ding, Y., Yu, L., & Liu, B. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.12.004 · Cited by 106
Martín‐Fernández, J. M., Balkenende, A., Verschoor, T., Lallemand, F., & Michalides, R. J. A. M. (1999) · PubMed · Cited by 105
Sethi, G., Ahn, K. S., Chaturvedi, M., & Aggarwal, B. B. (2007) · Oncogene · doi:10.1038/sj.onc.1210544 · Cited by 104
Self-citationHinnis, A. R., Luckett, J., & Walker, R. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603616 · Cited by 102
Nelson, J. M., & Fry, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008786200 · Cited by 102
Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes.
Chen, X., Shen, B., Xia, L., Khaletzkiy, A., Chu, D. T. W., Wong, J. Y. C., & Li, J. J. (2002) · PubMed · Cited by 102
Belyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 101
Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor
An, J., Chervin, A. S., Nie, A., Ducoff, H. S., & Huang, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209830 · Cited by 99
Sadzuka, Y., Sugiyama, T., & Sonobe, T. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00290-8 · Cited by 99
NF-κB as a target for cancer therapy
Melisi, D., & Chiao, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.133 · Cited by 99
Cell Stress and MEKK1-mediated c-Jun Activation Modulate NFκB Activity and Cell Viability
Sánchez‐Pérez, I., Benitah, S. A., Martínez-Gomáriz, M., Lacal, J. C., & Perona, R. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-01-0022 · Cited by 98
Inhibition of NF- B, Clonogenicity, and Radiosensitivity of Human Cancer Cells
Pajonk, F., Pajonk, K., & McBride, W. H. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1956 · Cited by 98
Tyrosine Nitration of IκBα: A Novel Mechanism for NF-κB Activation ,
Yakovlev, V. A., Barani, I. J., Rabender, C. S., Black, S. M., Leach, J. K., Graves, P. R., Kellogg, G. E., & Mikkelsen, R. B. (2007) · Biochemistry · doi:10.1021/bi701107z · Cited by 97
Radiosensitization of Human Melanoma Cells by Ribozyme-Mediated Inhibition of Survivin Expression
Pennati, M., Binda, M., Colella, G., Folini, M., Villa, R., Daidone, M. G., Zaffaroni, N., & Citti, L. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12082.x · Cited by 97
Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells
Virrey, J. J., Guan, S., Li, W., Schönthal, A. H., Chen, T. C., & Hofman, F. M. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071079 · Cited by 96
Pajonk, F., & McBride, W. H. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00311-5 · Cited by 96
Raju, U., Nakata, E., Yang, P., Newman, R. A., Ang, K. K., & Milas, L. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03023-7 · Cited by 95
Müerköster, S. S., Arlt, A., Witt, M., Gehrz, A., Haye, S., March, C., Grohmann, F., Wegehenkel, K., Kalthoff, H., Fölsch, U. R., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10963 · Cited by 94
Nakata, E., Mason, K. A., Hunter, N. R., Husain, A., Raju, U., Liao, Z. X., Ang, K. K., & Milas, L. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.061 · Cited by 94
Guo, J., Verma, U. N., Gaynor, R. B., Frenkel, E. P., & Becerra, C. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0366 · Cited by 93
N. YAMAGISHI, J. M. A. H. T. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143374 · Cited by 93
Dai, Q., Ling, Y., Lia, M., Zou, Y.-Y., Kroog, G. S., Iwata, K. K., & Perez-Soler, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0993 · Cited by 92
Naruse, I., Ohmori, T., Ao, Y., Fukumoto, H., Kuroki, T., Mori, M., Saijo, N., & Nishio, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.10173 · Cited by 89
Akimoto, T., Nonaka, T., Ishikawa, H., Sakurai, H., Saitoh, J., Takahashi, T., & Mitsuhashi, N. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01560-1 · Cited by 89
Aravindan, N., Madhusoodhanan, R., Ahmad, S. N. S., Johnson, D. A., & Herman, T. S. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.4.5534 · Cited by 87
NF- κ B and chemoresistance: potentiation of cancer drugs via inhibition of NF- κ B
Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0094 · Cited by 86
Crokart, N., Radermacher, K. A., Jordan, B. F., Baudelet, C., Cron, G. O., Grégoire, V., Beghein, N., Bouzin, C., Féron, O., & Gallez, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1288 · Cited by 84
Mi, J., Zhang, X., Rabbani, Z. N., Liu, Y., Reddy, S. K., Su, Z. Z., Salahuddin, F. K., Viles, K. D., Giangrande, P. H., Dewhirst, M. W., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300320 · Cited by 84
Scaife, C. L., Kuang, J., Wills, J. C., Trowbridge, D. B., Gray, P., Manning, B. M., EICHWALD, E. J., Daynes, R. A., & Kuwada, S. K. (2002) · PubMed · Cited by 83
Bcl-Xshort is elevated following severe global ischemia in rat brains
Dixon, E. P., Stephenson, D. T., Clemens, J. A., & Little, S. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)01040-8 · Cited by 83
Cisplatin Mimics ARF Tumor Suppressor Regulation of RelA (p65) Nuclear Factor-κB Transactivation
Campbell, K. J., Witty, J., Rocha, S., & Perkins, N. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2234 · Cited by 79
Ahmed, K. M., Dong, S., Fan, M., & Li, J. J. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0291 · Cited by 78
Zhou, D., Brown, S. A., Yu, T., Chen, G., Barve, S. S., Kang, B. C., & Thompson, J. S. (1999) · PubMed · Cited by 75
Inhibition of the Canonical IKK/NFκB Pathway Sensitizes Human Cancer Cells to Doxorubicin
Tapia-Laliena, M. Á., González-Navarrete, I., Dalmases, A., Bosch, M., Rodríguez‐Fanjul, V., Rolfe, M., Ross, J. S., Mezquita, J., Mezquita, C., Bachs, O., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.18.4721 · Cited by 75
Dittmann, K., Mayer, C., Ohneseit, P., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.08.065 · Cited by 75
Raju, U., Nakata, E., Mason, K. A., Ang, K. K., & Milas, L. (2003) · PubMed · Cited by 74
Hopkins-Donaldson, S., Cathomas, R. L., Simões‐Wüst, A. P., Kurtz, S., Belyanskya, L., Stahel, R. A., & Zangemeister‐Wittke, U. (2003) · International Journal of Cancer · doi:10.1002/ijc.11209 · Cited by 73
Terakado, N., Shintani, S., Yano, J., Li, C., Mihara, M., Nakashiro, K., & Hamakawa, H. (2003) · Oral Oncology · doi:10.1016/j.oraloncology.2003.09.005 · Cited by 69
McLaughlin, N., Annabi, B., Bouzeghrane, M., Temme, A., Bahary, J.-P., Moumdjian, R. A., & Béliveau, R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.10.009 · Cited by 67
Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents
Sun, C., Chan, F., Briassouli, P., & Linardopoulos, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.004 · Cited by 67
Schön, M., Wienrich, B. G., Kneitz, S., Sennefelder, H., Amschler, K., Voehringer, V., Weber, O., Stiewe, T., Ziegelbauer, K. B., & Schön, M. P. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn174 · Cited by 63
Konstantinopoulos, P. A., Fountzilas, E., Pillay, K., Zerbini, L. F., Libermann, T. A., Cannistra, S. A., & Spentzos, D. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-59 · Cited by 61
Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells
Hövelmann, S., Beckers, T. L., & Schmidt, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601876 · Cited by 58
Geoerger, B., Gaspar, N., Opolon, P., Morizet, J., Devanz, P., Lécluse, Y., Valent, A., Lacroix, L., Grill, J., & Vassal, G. (2008) · International Journal of Cancer · doi:10.1002/ijc.23488 · Cited by 58
Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process
Nasu, S., Milas, L., Kawabe, S., Raju, U., & Newman, R. A. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00263-x · Cited by 57
Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells.
Li-guang, Z., Liu, P., Chen, B., Wang, Y., Wang, X., Chiriva‐Internati, M., Wachtel, M. S., & Frezza, E. E. (2008) · PubMed · Cited by 54
Zhao, J., Gong, L., Xie, C., Zhang, L., Su, H., Deng, X., & Wu, S. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.08.008 · Cited by 54
Tsuboi, Y., Kurimoto, M., Nagai, S., Hayakawa, Y., Kamiyama, H., Hayashi, N., Kitajima, I., & Endo, S. (2008) · Journal of neurosurgery · doi:10.3171/2008.8.jns17648 · Cited by 52
Cyclin D1 in low-dose radiation-induced adaptive resistance
Ahmed, K. M., Fan, M., Nantajit, D., Cao, N., & Li, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.265 · Cited by 51
Singh, B., Cook, K. R., Vincent, L., Hall, C. S., Berry, J. A., Multani, A. S., & Lucci, A. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.02.026 · Cited by 51
Söderlund, K., Pérez‐Tenorio, G., & Stål, O. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.1.25 · Cited by 50
Kuroda, H., Takeno, M., Murakami, S., Miyazawa, N., Kaneko, T., & Ishigatsubo, Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.015 · Cited by 50
Zand, H., Rahimipour, A., Salimi, S., & Shafiee, S. M. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9838-x · Cited by 49
EGF receptor targeting in therapy-resistant human tumors
Schmidt, M., & Lichtner, R. B. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00004-3 · Cited by 49
Sors, A., Jean‐Louis, F., Bégué, E., Parmentier, L., Dubertret, L., Dréano, M., Courtois, G., Bachelez, H., & Michel, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1419 · Cited by 49
Saito, T., Hama, S., Izumi, H., Yamasaki, F., Kajiwara, Y., Matsuura, S., Morishima, K., Hidaka, T., Shrestha, P., Sugiyama, K., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604160 · Cited by 47
Fukuyama, R., Ng, K. P., Cicek, M., Kelleher, C., Niculaita, R., Casey, G., & Sizemore, N. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20288 · Cited by 46
Arısan, E. D., Kütük, Ö., Tezil, T., Bodur, Ç., Telci, D., & Başağa, H. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0343-z · Cited by 44
Servidei, T., Riccardi, A., Mozzetti, S., Ferlini, C., & Riccardi, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23902 · Cited by 42
Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer
Ikeguchi, M., & Kaibara, N. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.6.661 · Cited by 42
UVB-Induced Activation of NF-κb Is Regulated by the IGF-1R and Dependent on P38 MAPK
Lewis, D. A., & Spandau, D. F. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701127 · Cited by 41 · cited 1×
“In the absence of ligand-activated IGF-1R, UVB irradiation leads to the induction of NF-κB p50:p50 homodimers and a p38dependent increased susceptibility to apoptosis [56].”
BackgroundCurcumin sensitizes multiple myeloma to chemotherapy
(2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-5-cor2 · Cited by 41
Bednarski, B. K., Ding, X., Coombe, K., Baldwin, A. S., & Kim, H. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0321 · Cited by 39
Flynn, V. J., Ramanitharan, A., Moparty, K., Davis, R., Sikka, S. C., Agrawal, K. C., & Abdel‐Mageed, A. B. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.2.317 · Cited by 38
UVB activation of NF-κB in normal human keratinocytes occurs via a unique mechanism
Lewis, D. A., & Spandau, D. F. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-006-0729-2 · Cited by 37
Yang, C.-T., Li, J., Weng, H.-H., Li, Y., Chen, H.-C., & Chen, M.-F. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2009.55 · Cited by 36
Chen, W., McBride, W. H., Chen, S.-M., Lee, K.-F., Hwang, T., Jung, S.-M., Shau, H., Liao, S.-K., Hong, J., & Chen, M. (2005) · Head & Neck · doi:10.1002/hed.20178 · Cited by 36
Gomez, L. A., Pozas, A. D. L., & Perez‐Stable, C. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0467 · Cited by 31
Radiotherapy in laryngeal carcinoma: Can a panel of 13 markers predict response?
Wildeman, M. A., Gibcus, J. H., Hauptmann, M., Begg, A. C., van Velthuysen, M. F., Hoebers, F. J. P., Mastik, M. F., Schuuring, E. M. D., van der Wal, J. E., & van den Brekel, M. W. M. (2009) · The Laryngoscope · doi:10.1002/lary.20069 · Cited by 25
Cited by
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
Self-citationStrategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Metadata
- Authors
- Li, F., & Sethi, G.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 1805
- Issue
- 2
- Pages
- 167-180
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2052828768
- Cited by
- 398
- References
- 207
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.